This field study to measure access to and use of medicines was undertaken in GHANA in May-June 2008. The study assessed information on the socio-economic level of households, and access to and use of medicines for acute and chronic conditions as well as opinions and perceptio...ns about medicines. The survey was conducted in six regions. In each region, six reference public heath care facilities were selected among those participating in the Level II Facility Survey that was carried out in parallel. Within defined distances from each reference public health care facility, households were selected by purposive cluster sampling. A total of 1065 household respondents were interviewed by means of a structured paper questionnaire
more
DHS Working Papers No. 114
Guidelines on post-exposure prophylaxis for HIV and the use of co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents, and children: recommendations for a public health approach : December 2014 supplement to the 2013 Consolidated guidelines on the use of antiretroviral drugs... for treating and preventing HIV infection.
more
NATIONAL TUBERCULOSIS AND LEPROSY PROGRAMME
This guideline includes 48 updated and new evidence-based recommendations related to MNS conditions. The guideline is targeted towards non-specialized health workers at primary- or secondary-level healthcare facilities, or those working at the district level including basic inpatient and outpatient ...services.
more
Antibiotics 2022, 11(3), 329; https://doi.org/10.3390/antibiotics11030329.
The authors found that the most-represented antibiotics on the Rwandan market were amoxicillin, co-trimoxazole and cloxacillin. No counterfeit antibiotics were found in this study. However, substandard batches with moderate ...deviations were found, suggesting that regular quality control of antibiotics is needed in Rwanda.
more
ATLAS on substance use (2010) — Resources for the prevention and treatment of substance use disorders
Accessed: 14.03.2019
ATLAS on substance use (2010)— Resources for the prevention and treatment of substance use disorder
Accessed: 14.03.2019
The new, all oral, 20-month MDR-TB regimens range from US $1,600* (using bedaquiline and linezolid for 6 months and levofloxacin as the fluoroquinolone) to US $2,100* (using linezolid for 12 months and moxifloxacin as the fluoroquinolone.
World Drug Report 2017
-1-
Accessed: 14.03.2019
ATLAS on substance use (2010) — Resources for the prevention and treatment of substance use disorders
Accessed: 14.03.2019
with recommended essential medicines for common diseases in patients in Stockholm County Council (Healthcare Region), Sweden